Thymagen (Thymogen)

Key points

• Thymogen (also written Thymagen) is a short peptide linked to thymus activity and the immune system.
• It is one of the Russian peptide bioregulators, marketed for immune support.
• Most of the research comes from one group, and independent evidence is limited.
• It is not a licensed medicine in the UK and is sold for research use.

Quick facts

What it is

Thymus peptide bioregulator

Marketed for

Immune support

UK status

Not a licensed medicine; sold for research use

Human evidence

Mostly from one research group

How it works

The thymus helps direct the immune system. Thymogen is a short thymus related peptide said to support this activity. As with the other bioregulators, how well it works in people, and exactly how, is not well established outside its country of origin.

What the evidence shows

There are studies from Russia reporting immune effects, but independent trials of the kind needed to license a medicine in the UK are lacking. The claims should be treated with caution.

What it does not settle

• Independent evidence outside its country of origin is limited.
• Long term safety in wide use is not well established.
• Products sold online are not quality assessed.

Side effects

Less common but serious

• Because there is no UK licensed product, the dose, purity and contents of material bought online cannot be verified.

Report any suspected side effect through the MHRA Yellow Card scheme.

UK legal status and access

Thymogen has no UK marketing authorisation, so it is not a licensed medicine and is not offered by registered clinics or pharmacies. It is sold online for research use.

Common questions